Thursday, 8 April 2021
The European Medicines Agency (EMA) on Wednesday acknowledged a "possible link" between the AstraZeneca vaccine and "very rare cases of blood clots" but said the benefits of the vaccine, however, continue to outweigh the risks.
According to a statement from the European medical body, the Pharmacovigilance Risk Assessment Committee (PRAC) "concluded on Wednesday that unusual blood clots with low blood platelets should be listed as very rare side effects of Vaxzevria (formerly Covid-19 Vaccine AstraZeneca)."
"In reaching its conclusion, the committee took into consideration all currently available evidence, including the advice from an ad hoc expert group," it added.
EMA said that it is reminding healthcare professionals and people receiving the vaccine to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within two weeks of vaccination.